Evaluation of PBMC Distribution and TLR9 Expression in Patients with Systemic Lupus Erythematosus
-
Sahar Mortezagholi
,
Zohreh Babaloo
,
Parisa Rahimzadeh
,
Mojgan Ghaedi
,
Hayedeh Namdari
,
Shirin Assar
,
Maryam Azimi Mohamadabadi
,
Eisa Salehi
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which results in damage to various organs. Some animal studies have revealed that activation of Toll-like receptors (TLRs) is important in the pathogenesis of SLE. In the present study, the percentage of different immune cell subsets in 35 SLE patients and 38 control subjects was analyzed by flow cytometry. We also assessed the expression of TLR9 in the population of peripheral blood mononuclear cells (PBMCs) including T lymphocytes (CD4+ and CD8+), B lymphocytes (CD19+), NK cells (CD56+) and monocytes (CD14+) in SLE patients and healthy controls. The results showed that the percentage of CD8+ T lymphocytes and CD14+ monocytes were significantly higher (p˂0.001) in the SLE patients than the healthy control subjects. Moreover, the percentage of CD56+ NK cells were significantly lower in the SLE patients than the healthy control subjects (p=0.001). The findings indicated that the expression of TLR9 was significantly higher in CD4+ and CD8+ T lymphocytes and CD19+ B lymphocytes of SLE patients than in control subjects (all p˂0.05). The difference in TLR9 expression are involved in pathogenesis of the SLE, hence it can be used as an indicator for SLE diagnosis.
1. Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56(7):481-90.
2. Means TK, Luster AD. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann N Y Acad Sci 2005; 1062:242-51.
3. Crispín JC, Liossis S-NC, Kis-Toth K, Lieberman LA,Kyttaris VC, Juang Y-T, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16(2):47-57.4. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21(1):231-64.
5. Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol 2004;4(10):825-31.
6. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307(5709):590-3.
7. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6(11):823-35.
8. Christensen SR, Shlomchik MJ, editors. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007; 19(1):11-23.
9. Guggino G, Giardina AR, Ciccia F, Triolo G, Dieli F, Sireci G. Are toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes? Clin Dev Immunol 2011; 2012:135932.
10. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21(1):335-76.
11. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR- independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13(5):543-51.
12. Kim WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev 2009 ; 8(3):204-8.
13. Rahman AH, Eisenberg RA. The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol 2006; 28(2):131-43.
14. Liossis S, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101(7):1448-57.
15. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res 2014; 2014.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D,Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35(6):630-40.
17. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytesexpressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52(1):201-11.
18.Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross- presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195(1):125-33.
19. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009; 60(6):1753-63.
20. Green M, Kennell A, Larche M, Seifert M, Isenberg D, Salaman M. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005; 141(1):165-73.
21. Gonzalez-Amaro R, Alcocer-Varela J, Alarcon-Segovia D. Natural killer cell activity in the systemic connective tissue diseases. J Rheumatol 1988; 15(8):1223-8.
22. Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani‐Dalbin P, et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon‐γ production in patients with active disease. Arthritis Rheum 2011; 63(6):1698-706.
23. Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz) 2010; 58(5):355-64.
24. Byrne JC, Ní Gabhann J, Lazzari E, Mahony R, Smith S, Stacey K, et al. Genetics of SLE: functional relevance for monocytes/macrophages in disease. Clin Dev Immunol 2012; 2012:582252.
25. Klonowska-Szymczyk A, Wolska A, Robak T, Cebula-Obrzut B, Smolewski P, Robak E. Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Mediators Inflamm 2014; 2014.
26. Wong C, Wong P, Tam L, Li E, Chen D, Lam C. Activation profile of Toll‐like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010; 159(1):11-22.
27. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 2004; 101(9):3029-34.
28. Chuang T-H, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 2004; 5(5):495-502.
29. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G,Tsatsanis C, Gergianaki I, et al. Expansion of toll‐like receptor 9–expressing B cells in active systemic lupus erythematosus: Implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54(11):3601-11.
30. Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34(3):493-500.
31. Nakano S, Morimoto S, Suzuki J, Nozawa K, Amano H, Tokano Y, et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 2008; 47(2):145-9.32. Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun 2012; 39(3):206-15.
33. Richez C, Blanco P, Rifkin I, Moreau J-F, Schaeverbeke T. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine 2011; 78(2):124-30.
34. Tadema H, Abdulahad WH, Stegeman CA, Kallenberg CG, Heeringa P. Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PloS one 2011; 6(9):e24315.
35. Voynova EN, Skinner J, Bolland S. Expansion of an Atypical NK Cell Subset in Mouse Models of Systemic Lupus Erythematosus. J Immunol 2015; 194(4):1503-13.
| Files | ||
| Issue | Vol 15, No 3 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Autoimmunity Lymphocyte Monocyte Systemic lupus erythematosus Toll-like receptor 9 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
